AI-Powered PMD Act & FDA Audit Response
1,200 Hours Saved in Corrective Actions
CASE OVERVIEW
Implementation Overview and Key Results
Industry
Medical Devices
Departments
QA, Regulatory, Development
Timeline
8-week PoC, 6-month rollout
Audit workload
1,200 hrs/year saved
CAPA search time
45 min → 3 min
Overseas inquiries
90 → 18/month
REGULATORY CONTROL
Structural improvement of the regulatory compliance process
PMD Act / FDA QSR / MDR
PHASE
01
The medical device industry faces complex compliance requirements under regulations such as Japan’s PMD Act, FDA QSR, and the EU Medical Device Regulation (MDR). The ability to immediately present large volumes of supporting documents during audits is essential for business continuity.
PHASE
02
At Company G, the regulatory affairs team was forced into late-night overtime every time audit preparation began. With veteran regulatory staff approaching retirement, a fundamental review of the regulatory compliance process had become urgent.
PHASE
03
This case shows how introducing CLAVI Mining structurally improved the regulatory compliance process itself.
Challenges Before Implementation
AUDIT RISK 01
For audits and inspections by domestic and overseas regulatory authorities, the company needed to immediately present past corrective action records, design validation records, and risk management documents. However, documents had been scattered for more than 10 years, causing over 200 person-hours of preparation for each audit. Late-night overtime in the regulatory affairs department exceeded an annual average of 180 hours per person, and health risks had become visible.
AUDIT RISK 02
In addition, when aligning pharmaceutical and medical device regulations with overseas subsidiaries, local staff frequently contacted the headquarters regulatory affairs team, putting pressure on headquarters resources. Local staff pointed out that waiting for responses from Japan headquarters had become a bottleneck in local audit responses.
AUDIT RISK 03
Veteran regulatory affairs staff were approaching retirement, making the transfer of tacit regulatory know-how a major issue. At the development executive level, people were asking, “What will happen to FDA responses after that person retires?”
Reasons for Selection
REASON 01
The most important selection criterion for Company G was the “transparency log.” In FDA inspections, the ability to explain the basis for AI use is increasingly important, and CLAVI Mining’s audit API and evidence presentation functions could be used directly for inspection response.
REASON 02
In addition, the hallucination-prevention patent became a decisive basis for meeting governance requirements in the life-critical field of medical devices. During the PoC, the company also conducted preliminary hearings with a third-party audit organization for internal quality management regarding AI use. The view that “AI can be included in the audit scope if proper governance is in place” strongly supported management’s decision.
REASON 03
CLAVI Mining was also evaluated highly because the vendor had multiple implementation records in the medical device industry and had accumulated experience addressing industry-specific regulatory requirements.
Post-Implementation Results
EFFECT 01
【Audit preparation workload】1,200 hours saved annually. Late-night overtime in the regulatory affairs department almost disappeared, and mental health indicators improved significantly.
EFFECT 02
【Corrective action search time】Average time per case reduced from 45 minutes to 3 minutes, a 93% reduction. The team can now present evidence on the spot even for follow-up questions from auditors, greatly improving the speed of audits.
EFFECT 03
【Overseas subsidiary inquiries】Reduced from 90 to 18 per month, an 80% decrease. The workload of the headquarters regulatory affairs team was greatly reduced, freeing time for strategic work such as regulatory trend research and internal training.
EFFECT 04
【Regulatory know-how succession】The knowledge of veteran regulatory affairs staff is continuously accumulated in AI, increasing the percentage of cases that younger regulatory staff can lead independently. A veteran scheduled for retirement also gave high praise, saying, “Knowing that my experience will remain in the organization lets me give my all in my final year.”
Comment from the Head of Quality Assurance
“For medical devices, everything depends on whether the answer has evidence. Because CLAVI has patented technology and transparency logs, we can confidently use it for regulatory authority responses. Going forward, we also want to expand its use to clinical trial document management.”
Insights from This Case and Future Development
Insights from this case and
future development
The essence of Company G’s case is the discovery that “regulatory compliance can become the strongest tailwind for AI adoption.” Traditionally, regulatory compliance was seen as a barrier to AI implementation. However, by choosing AI equipped with transparency logs and evidence presentation as standard features, companies can improve both the efficiency and accuracy of regulatory compliance. This insight applies not only to medical devices, but also to all highly regulated industries such as chemicals, food, and automotive.
Starting with regulatory affairs and quality assurance departments, Company G is expanding adoption to development, clinical trials, and technical sales departments. The company is now redesigning the entire regulatory compliance workflow with AI, including clinical trial document management, technical inquiry support for medical institutions, and support for preparing application documents for overseas authorities.
Especially for FDA and EU MDR compliance, collaboration with overseas subsidiaries is essential, and multilingual support provides major benefits. The organizational capability to balance the quality and speed of regulatory compliance is now positioned as a core source of future business competitiveness. Regulatory compliance AI is becoming a foundational technology that supports business continuity in the medical device industry.